Exposure-response model for the effect of AZD5069, a novel CXCR2 antagonist, on neutrophil count in asthma patients

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-A-106-Monday
• By: WAHLBY HAMREN, Ulrika (AstraZeneca R&D, Early Clinical Development, Mölndal, Sweden)
• Co-author(s): Ulrika Wahlby Hamren: Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
  Justin Wilkins: Occams, Amstelveen, Netherlands;, SGS Exprimo NV, Mechelem, Belgium
  Bengt Larsson: RIA TMU, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
  Marie Cullberg: Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
  
• Abstract:

  Backgrounds

  AZD5069 is a reversible oral CXCR2 antagonist that blocks neutrophil migration and reduces circulating neutrophil counts [1]. Models describing neutrophil dynamics after cytotoxic drug intervention have previously been published [2], however these are not applicable for the CXCR2 mechanism of action.

  Aims

  We developed a population
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login